Jane Street Group LLC Sells 16,550 Shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)

Jane Street Group LLC reduced its stake in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 11.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 127,184 shares of the company’s stock after selling 16,550 shares during the quarter. Jane Street Group LLC owned about 1.74% of Global X Genomics & Biotechnology ETF worth $1,431,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the stock. One Capital Management LLC grew its holdings in Global X Genomics & Biotechnology ETF by 22.1% in the second quarter. One Capital Management LLC now owns 680,311 shares of the company’s stock worth $7,102,000 after purchasing an additional 123,339 shares during the period. Flow Traders U.S. LLC purchased a new position in shares of Global X Genomics & Biotechnology ETF during the third quarter valued at approximately $936,000. Oppenheimer Asset Management Inc. grew its holdings in Global X Genomics & Biotechnology ETF by 10.2% during the second quarter. Oppenheimer Asset Management Inc. now owns 67,712 shares of the company’s stock worth $707,000 after buying an additional 6,260 shares in the last quarter. Corrado Advisors LLC raised its position in Global X Genomics & Biotechnology ETF by 3.0% in the 3rd quarter. Corrado Advisors LLC now owns 64,224 shares of the company’s stock valued at $723,000 after buying an additional 1,894 shares during the last quarter. Finally, Sanctuary Advisors LLC bought a new position in Global X Genomics & Biotechnology ETF during the 2nd quarter valued at $590,000. 56.95% of the stock is currently owned by institutional investors.

Global X Genomics & Biotechnology ETF Price Performance

GNOM opened at $9.84 on Friday. Global X Genomics & Biotechnology ETF has a 1 year low of $9.52 and a 1 year high of $12.53. The company has a market capitalization of $71.93 million, a price-to-earnings ratio of -4.21 and a beta of 1.03. The firm’s fifty day moving average price is $10.40 and its two-hundred day moving average price is $10.81.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.